English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dear Editor, As known, pain due to subcutaneous (s.c.) injections is often more severe and the most common reason for patient noncompliance, other than erythema, edema, hematoma, and pruritus.[1] Advances in formulation of injection are targeted at developing injectables which can cause minimal discomfort. Buffers are ideally used in injectable formulations to prevent the pH‐associated degradation of the active ingredient(s) and improve the stability of the product. The choice of buffers includes citrates, carbonates, acetates, histidine, sodium bicarbonate, and phosphates. One of the contributing factors for injection site pain is the buffers which are ideally used to prevent the pH‐associated degradation of the active ingredient(s) and improve the stability of the product. A placebo‐controlled clinical trial of adalimumab (Humira) in Rheumatoid Arthritis (RA) patients have shown that its s.c. injection leads to injection site reaction, including erythema and/or itching, hemorrhage, related pain, and swelling.[2] The objective of this study was to understand the injection site pain with Succinate buffer‐based formulation of adalimumab biosimilar (ZRC‐3197) and compare it with the existing data on citrate buffer. We carried out an observational study, where a prospective questionnaire‐based study in patients treated with adalimumab injection for different rheumatological conditions was carried out. Patients aged ≥12 years of either sex, who had received at least three doses of injection, were included. The study duration was over 6 months. Data pertaining to pain at the site of injection were collected with the aid of two questionnaires distributed to the patients. Primary objective was describing pain at the site within 24 h of injection. Pain was assessed using the 0–10 numeric pain rating scale (National Initiative on Pain ControlTM)[3] and verbal description pain scale. Study was approved by the Intersystem Biomedica Ethics Committee (IEC No: ISBEC/ NR‐3/DDJJ/2018, Date of approval: 09‐02‐2018).

Reduced Injection Site Pain with Succinate Buffer-Based Adalimumab Biosimilar (ZRC-3197) Injection (SUFFER Study): An Observational Study